Shree Ganesh Remedies Ltd (SGRL) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Shree Ganesh Remedies Ltd on NSE and BSE, with an AI summary of each filing.
Investor Presentation
Investor Presentation · 02 Nov 2026, 12:38 am
Shree Ganesh Remedies Reports Q2 & H1FY27 Financial and Operational Performance Shree Ganesh Remedies reported Q2FY27 revenue from operations of ₹23.29 crore, down 23% YoY but rebounding 62% QoQ. Operating EBITDA declined 59% YoY to ₹3.94 crore with EBITDA margins contracting 1,483 bps YoY to 16.9%, impacted by subdued European demand and input cost volatility. PAT fell 67% YoY to ₹1.63 crore. For H1FY27, revenue stood at ₹37.65 crore (-32% YoY) and PAT at ₹2.75 crore (-67% YoY). Growth catalysts include commercializing two pharma intermediates, expanding CRAMS pipelines, completing Block 7A construction, and phased Dahej expansion.
Press Release
Press Release · 02 Nov 2026, 12:37 am
Shree Ganesh Remedies Reports Weak Q2FY27 Results Amid Input Cost Pressures Shree Ganesh Remedies reported a challenging Q2FY27, with revenue declining 23% YoY to ₹23.29 Cr, EBITDA dropping 59% YoY to ₹3.94 Cr, and PAT falling 67% YoY to ₹1.63 Cr. EBITDA margins contracted 1,483 bps YoY to 16.9%, impacted by volatile raw material costs and subdued European demand. However, performance rebounded QoQ, with revenue rising 62% and PAT gaining 46%. H1FY27 revenue and PAT stood at ₹37.65 Cr and ₹2.75 Cr, down 32% and 67% YoY, respectively. Construction of Block 7A is completed to support its expanding CRAMS pipeline.
Financial Results for quarter and half year ended September 30, 2026
Financial Result · 01 Nov 2026, 1:05 am
Shree Ganesh Remedies Reports Q2 FY27 Financial Results Shree Ganesh Remedies reported standalone revenue from operations of ₹2,329.47 lakhs for the quarter ended 30th Sep'26, up 62.22% QoQ from ₹1,436.00 lakhs but down 23.16% YoY from ₹3,031.50 lakhs. Standalone Net Profit stood at ₹163.46 lakhs (EPS of ₹1.28), rising 45.93% QoQ from ₹112.01 lakhs while declining 67.02% YoY from ₹495.57 lakhs. Consolidated revenue was ₹2,329.47 lakhs with a Net Profit of ₹162.99 lakhs. For H1 ended 30th Sep'26, consolidated revenue reached ₹3,765.47 lakhs and Net Profit totaled ₹275.00 lakhs.
Outcome of Board Meeting
Outcome · 31 Oct 2026, 10:51 pm
Shree Ganesh Remedies Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh) ■ Revenue: 2,329 (-23.2% YoY | +62.2% QoQ) ■ EBITDA: 394 (-59.1% YoY | +17.4% QoQ) ■ EBITDA Margin (%): 16.9 (-1483 bps YoY | -645 bps QoQ) ■ PAT: 163 (-67.1% YoY | +45.5% QoQ) ■ EPS (INR): 1.27 (-67.1% YoY | +46.0% QoQ)
Shree Ganesh Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/10/2026 ,inter alia, to consider and approve The Unaudited Financial ....
Intimation · 31 Oct 2026, 5:30 am
Shree Ganesh Remedies Schedules Board Meeting for Q2 FY27 Financial Results Shree Ganesh Remedies Limited has scheduled its Board of Directors meeting on 31st Oct'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26. In compliance with insider trading regulations, the trading window for dealing in company shares has been closed since 1st Oct'26 and will remain closed until 48 hours post-declaration of the financial results.
Appointment of Company Secretary and Compliance Officer
Change in Management · 04 Oct 2026, 12:56 am
Shree Ganesh Remedies Appoints Ms. Akanksha as CS and Compliance Officer Shree Ganesh Remedies Limited approved the resignation of Mr. Aditya Vikrambhai Patel from the position of Company Secretary and Compliance Officer (KMP), effective close of business on 3rd Oct'26, as he pursues external career opportunities. The Board appointed Ms. Akanksha (ICSI Membership No. A81722) as the new Company Secretary, Compliance Officer, and KMP, effective 4th Oct'26. She holds B.Com. and LL.B. degrees with practical experience in corporate governance, ROC filings, and SEBI listing compliances.
Resignation of Company Secretary / Compliance Officer
Change in Management · 04 Oct 2026, 12:54 am
Shree Ganesh Remedies Appoints Ms. Akanksha as CS and Compliance Officer Shree Ganesh Remedies Limited's Board of Directors approved key managerial personnel changes on 3rd Oct'26. Mr. Aditya Vikrambhai Patel resigned as Company Secretary and Compliance Officer, effective close of business on 3rd Oct'26, to pursue outside career opportunities. Concurrently, the Board approved the appointment of Ms. Akanksha (ICSI Membership No. A81722) as the new Company Secretary and Compliance Officer (KMP), effective 4th Oct'26. Ms. Akanksha holds B.Com and LL.B. degrees alongside expertise in corporate governance and SEBI regulatory compliances.
Outcome of Board Meeting
Others (Uncategorized) · 04 Oct 2026, 12:50 am
Shree Ganesh Remedies Announces Key Managerial Personnel Transition Shree Ganesh Remedies Limited approved the resignation of Mr. Aditya Vikrambhai Patel as Company Secretary and Compliance Officer (Key Managerial Personnel), effective close of business on 3rd Oct'26, as he pursues external opportunities. Concurrently, the Board approved the appointment of Ms. Akanksha (ICSI Membership No. A81722) as Company Secretary and Compliance Officer (KMP), effective 4th Oct'26. Ms. Akanksha holds B.Com and LL.B. degrees with relevant expertise in corporate secretarial functions, SEBI listing regulations, ROC filings, and corporate governance compliance. Neither individual holds shares in the company.
Voting Results
Annual General Meeting · 13 Sept 2026, 2:14 am
Shree Ganesh Remedies Shareholders Approve All 31st AGM Resolutions with Overwhelming Majority Shree Ganesh Remedies announced the voting results for its 31st AGM held on 12th Sep'26, where shareholders approved all four proposed resolutions with ~100% majority. Key approvals included the adoption of audited standalone and consolidated financial statements for FY26 (99.9999% in favour on 79.10% voter turnout), the re-appointment of retiring director Chandulal Manubhai Kothia, ratification of remuneration for Cost Auditors M/s. M.I. Prajapati & Associates LLP for FY27, and the appointment of Ms. Hiral Ankitkumar Shah as an Independent Director via special resolution (99.9999% in favour).
Proceedings of Annual General Meeting of the Company
Annual General Meeting · 12 Sept 2026, 9:54 pm
Annual Report FY 2025-26
Others (Uncategorized) · 21 Aug 2026, 2:15 am
Investor Presentation
Investor Presentation · 13 Aug 2026, 6:04 pm
Q1FY27 Results Weighed Down by Subdued European Demand Shree Ganesh Remedies reported a challenging Q1FY27, with revenue declining 42% YoY to ₹14.36 crore and PAT falling 68% to ₹1.12 crore. The weakness was driven by subdued European demand and customer order deferrals amid geopolitical uncertainty. EBITDA margin contracted sharply by 624 bps YoY to 23.3%. Management has moderated its FY27 growth guidance but expects a meaningful performance improvement in H2FY27. This is driven by the termination of a distributor agreement, allowing direct customer engagement, and anticipated revenue contributions from new CRAMS projects.
Press Release
Press Release · 13 Aug 2026, 6:02 pm
Shree Ganesh Remedies Q1FY27 Results Weighed Down by Subdued European Demand Shree Ganesh Remedies reported weak Q1FY27 results, impacted by subdued European demand and customer order deferrals. Revenue declined 42% YoY to ₹14.36 Cr, with EBITDA falling 54% to ₹3.35 Cr. EBITDA margin contracted by 624 bps YoY to 23.3%. Profit After Tax (PAT) dropped 68% YoY to ₹1.12 Cr. The company noted the termination of an EU distributor agreement and expects a recovery in the second half of FY27, driven by new CRAMS projects and direct customer engagement, while moderating its full-year growth guidance.
Appointment of Cost Auditors
Change in Auditor · 12 Aug 2026, 11:41 pm
Shree Ganesh Remedies Board Approves Q1 Results and Appoints Cost Auditors The Board of Shree Ganesh Remedies met on 12th Aug'26 to approve Q1 results for the period ending 30th Jun'26. The board also appointed M/s. M. I. Prajapati & Associates LLP as Cost Auditors for FY26-27. Additionally, the notice for the 31st Annual General Meeting was approved. For Q1 FY27, on a consolidated basis, revenue from operations was ₹1,436.00 lakhs and profit after tax stood at ₹112.01 lakhs. The company reported a basic and diluted EPS of ₹0.87 for the quarter.
Financial Results for the quarter ended on June 30, 2026
Financial Result · 12 Aug 2026, 11:36 pm
Shree Ganesh Remedies Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakhs) ■ Revenue: 1,436 (-41.8% YoY | -56.7% QoQ) ■ EBITDA: 335 (-54.1% YoY | -70.5% QoQ) ■ EBITDA Margin (%): 23.3 (-624 bps YoY | -1092 bps QoQ) ■ PAT: 112 (-67.5% YoY | -82.1% QoQ) ■ EPS (INR): 0.87 (-67.5% YoY | -82.2% QoQ)
Outcome of Board Meeting
Outcome · 12 Aug 2026, 11:30 pm
Shree Ganesh Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve the Unaudited (Standalone ....
Intimation · 12 Aug 2026, 5:30 am
Shree Ganesh Remedies Board Meeting Scheduled for Q1FY27 Results Shree Ganesh Remedies (BSE: 540737) will hold a Board of Directors meeting on 12 Aug'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter ended 30 Jun'26. In connection with this, the trading window for insiders has been closed since 01 Jul'26 and will reopen 48 hours after the financial results are publicly announced.
Appointment of Additional Director (Non executive, Independent)
Change in Management · 17 Jul 2026, 9:27 pm
Shree Ganesh Remedies Appoints New Non-Executive Independent Director Shree Ganesh Remedies (BSE: 540737) appointed Ms. Hiral Ankitkumar Shah as an Additional and Non-Executive Independent Director, effective 17 Jul'26. The appointment is for a five-year term, pending shareholder approval. Ms. Shah, a qualified Company Secretary with over 14 years of experience, specializes in corporate governance, legal, and regulatory compliance for listed companies. She currently serves as Company Secretary and Compliance Officer at UMA Converter Limited and is not debarred by any SEBI order.
Clarification
Others (Uncategorized) · 30 Jun 2026, 2:38 am
Shree Ganesh Remedies Clarifies Share Price Movement Shree Ganesh Remedies (Scrip: 540737) responded on Jun 29, '26 to a BSE clarification sought on Jun 25, '26 regarding significant share price movement. The company stated the price volatility is purely market-driven and that its management has no control over or knowledge of the specific reasons behind it. Shree Ganesh Remedies affirmed its commitment to continue making all required disclosures under Regulation 30 of SEBI Listing Regulations and will comply with all stock exchange agreements.
Intimation of Schedule of Analyst /Institutional Investor Meetings
Intimation · 26 Jun 2026, 1:09 am
Shree Ganesh Remedies to Meet Moneybee Investment Advisors Shree Ganesh Remedies (BSE: 540737) management will hold a meeting with institutional investor Moneybee Investment Advisors on Jun 30, '26. The meeting, disclosed under SEBI regulations, is scheduled to take place in Ankleshwar.
The Exchange has sought clarification from Shree Ganesh Remedies Ltd on June 25, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....
Others (Uncategorized) · 25 Jun 2026, 10:54 pm
Transcript of Earnings Call
Transcript · 21 May 2026, 1:51 am
Audio Recording - Earnings Call held on May 15, 2026
Audio / Video · 16 May 2026, 8:41 pm
Shree Ganesh Remedies provides audio recording for May 15 earnings call Shree Ganesh Remedies Limited (BSE: 540737) submitted a regulatory filing on 16 May'26, providing the audio recording link for its earnings call held on 15 May'26. The communication, addressed to the BSE, makes the discussion from the investor and analyst conference call publicly available. This filing ensures compliance with regulatory disclosure requirements following the announcement of the company's financial results. Further details on performance and outlook were discussed on the call.
Press Release
Press Release · 15 May 2026, 6:19 pm
Shree Ganesh Remedies Q4FY26 Results Show Strong Revenue Growth, Margin Pressure Shree Ganesh Remedies reported mixed Q4FY26 results with revenue up 36% YoY to ₹33.20 Cr, driven by strong QoQ recovery. However, PAT declined 5% YoY to ₹6.27 Cr. EBITDA margin contracted significantly by 616 bps YoY to 34.3% due to higher operating expenses. For the full year FY26, revenue was flat at ₹109.29 Cr, while PAT fell 23% to ₹17.77 Cr, and EBITDA margin dropped 406 bps to 32.0%. The company noted progress in CRAMS projects and expects its Block 7 expansion to commence production from Q2FY27.
Investor Presentation
Investor Presentation · 15 May 2026, 1:21 am
Shree Ganesh Remedies Reports Strong Q4FY26 Amidst Full-Year Consolidation For Q4FY26, Shree Ganesh Remedies reported revenue of ₹33.20 crores, up 36% YoY, with EBITDA at ₹11.37 crores, a 15% YoY increase. However, PAT declined 5% YoY to ₹6.27 crores. For the full year FY26, revenue was flat at ₹109.29 crores (+1% YoY), while EBITDA fell 11% to ₹35.02 crores, and PAT dropped 23% to ₹17.77 crores. The EBITDA margin contracted by 406 bps to 32.0%. Management noted FY26 as a consolidation year, with progress in CRAMS projects and capacity expansion on track.